Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

1b , BCL-2 was the only member that was commonly and consistently induced in the 3 nADT datasets and showed a trend of upregulation in Enza-resistant PCa.

also in 53,322 other papers

We then examined BCL-2 levels in 422 untreated primary tumors in TCGA-PRAD, which displayed an increasing trend that correlated with tumor grade (i.e., combined Gleason Score, GS) as supported by Jonckhere-Terpstra (J-T) trend test (Fig. 1a ).

also in 63,971 other papers